In the latest trading session, Humacyte, Inc. (HUMA) closed at $1.77, marking a -4.84% move from the previous day. This change lagged the S&P 500's daily gain of 0.44%. Meanwhile, the Dow experienced a rise of 0.14%, and the technology-dominated Nasdaq saw an increase of 0.7%.
The stock of company has risen by 17.72% in the past month, leading the Medical sector's gain of 1.25% and the S&P 500's gain of 4.03%.
The investment community will be paying close attention to the earnings performance of Humacyte, Inc. in its upcoming release. The company's earnings per share (EPS) are projected to be -$0.17, reflecting a 48.48% increase from the same quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.35 per share and a revenue of $3.51 million, signifying shifts of +66.67% and 0%, respectively, from the last year.
Any recent changes to analyst estimates for Humacyte, Inc. should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Currently, Humacyte, Inc. is carrying a Zacks Rank of #4 (Sell).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 101, this industry ranks in the top 41% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Humacyte, Inc. (HUMA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
